AC
Publications
383
Views
136,372
Downloads
45,126
Supervised works
2
Items per page
1 - 383 of 383
Title Published in Access level OA Policy Year Views Downloads
Gender and geographical bias in the editorial decision-making process of biomedical journals : a case-control studyBMJ evidence-based medicine
accessLevelPublic
2024 32 43
Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort : a prospective observational cohort studyThe lancet. HIV
accessLevelRestricted
2024 83 0
Infectious disease events in people with HIV receiving kidney transplantation : Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort StudyBMC infectious diseases
accessLevelPublic
2024 57 70
Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV) : a multicenter, international, non-randomized clinical trial study protocolBMC infectious diseases
accessLevelPublic
2024 118 75
Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIVClinical pharmacology and therapeutics
accessLevelPublic
2024 86 27
Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3)The journal of infectious diseases
accessLevelPublic
2024 509 399
Study protocol for assessment of the efficacy of calcium dobesilate versus placebo on SARS-CoV-2 viral load in outpatients with COVID-19 (CADOVID study): a randomised, placebo-controlled, double-blind, monocentric phase II trialBMJ open
accessLevelPublic
2024 20 55
Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1Journal of antimicrobial chemotherapy
accessLevelRestricted
2023 90 0
Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral TherapyClinical infectious diseases
accessLevelPublic
2023 98 75
Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV) : A Study Combining Modelling and Swiss HIV Cohort DataClinical infectious diseases
accessLevelPublic
2023 108 56
Viral suppression and retention in HIV care during the postpartum period among women living with HIV : a longitudinal multicenter cohort studyThe Lancet regional health. Europe
accessLevelPublic
2023 58 11
VIH : zoom sur les traitements injectables à longue durée d’actionRevue médicale suisse
accessLevelPublic
2023 112 95
Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor‐containing regimenBritish journal of clinical pharmacology
accessLevelPublic
2023 100 49
Mpox in people with advanced HIV infection: a global case seriesLancet
accessLevelPublic
2023 134 200
External validation of the Dat'AIDS score : A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or olderHIV medicine
accessLevelPublic
2023 90 52
Low prevalence of asymptomatic mpox in populations at high riskThe Lancet microbe
accessLevelPublic
2023 114 32
An Automated Literature Review Tool (LiteRev) for Streamlining and Accelerating Research Using Natural Language Processing and Machine Learning: Descriptive Performance Evaluation StudyJMIR. Journal of medical internet research
accessLevelPublic
2023 160 124
Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-studyBMC pharmacology & toxicology
accessLevelPublic
2023 58 75
Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV CoinfectionClinical infectious diseases
accessLevelRestricted
2023 107 0
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialCritical care
accessLevelPublic
2023 80 44
Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohortHIV medicine
accessLevelPublic
2023 85 80
Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort studyAIDS
accessLevelPublic
2023 112 35
Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV : The Swiss HIV Cohort StudyThe Journal of infectious diseases
accessLevelPublic
2023 91 19
Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2)Open forum infectious diseases
accessLevelPublic
2023 82 49
Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus (HIV) in SwitzerlandClinical infectious diseases
accessLevelPublic
2023 100 20
A Case of Mpox ReinfectionClinical infectious diseases
accessLevelPublic
2023 70 77
No time for complacency on COVID-19 in EuropeLancet
accessLevelPublic
2023 122 24
The international Unity study for antivirals against mpox is a blueprint for future epidemicsNature medicine
accessLevelRestricted
2023 124 0
Triggers of change in sexual behavior among people with HIV: The Swiss U = U statement and Covid-19 comparedThe journal of infectious diseases
accessLevelPublic
2023 111 60
Does menopause transition influence viral suppression and adherence in women living with HIV?Journal of acquired immune deficiency syndromes
accessLevelPublic
2023 81 14
Multicentric evaluation of a specific intrathecal anti-Treponema pallidum IgG index as a diagnostic biomarker of neurosyphilis: results from a retro-prospective case–control studySexually transmitted infections
accessLevelRestricted
2023 166 0
Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons With Human Immunodeficiency Virus (HIV): The Swiss HIV Cohort StudyClinical infectious diseases
accessLevelPublic
2023 97 34
Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2)Open forum infectious diseases
accessLevelPublic
2023 134 61
Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19Open forum infectious diseases
accessLevelPublic
2023 109 63
Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018The journal of antimicrobial chemotherapy
accessLevelPublic
2023 134 123
Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trialThrombosis research
accessLevelPublic
2023 312 60
SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant RecipientsVaccines
accessLevelPublic
2023 87 74
Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS)HIV medicine
accessLevelPublic
2022 142 90
Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trialTrials
accessLevelPublic
2022 130 99
Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variantsFrontiers in microbiology
accessLevelPublic
2022 252 49
Cardiovascular risk assessment in people living with HIV compared to the general populationEuropean journal of preventive cardiology
accessLevelPublic
2022 216 105
Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected IndividualsFrontiers in immunology
accessLevelPublic
2022 252 81
Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 EpidemicsJournal of acquired immune deficiency syndromes
accessLevelPublic
2022 183 51
An Approach to Quantifying the Interaction between Behavioral and Transmission ClustersViruses
accessLevelPublic
2022 90 17
CD4:CD8 Ratio and CD8 Cell Count and Their Prognostic Relevance for Coronary Heart Disease Events and Stroke in Antiretroviral Treated Individuals: The Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelPublic
2022 93 34
Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in SwitzerlandPharmaceutics
accessLevelPublic
2022 66 51
Immunocompromised patients have been neglected in COVID-19 trials: a call for actionClinical microbiology and infection
accessLevelPublic
2022 70 64
Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study: A Cross-Sectional StudyJournal of immigrant and minority health
accessLevelPublic
2022 89 59
La variole du singe: Une nouvelle épidémie – réponses aux questions fréquentes dans la pratiquePrimary and Hospital Care
accessLevelPublic
2022 206 69
A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimabLancet. Infectious diseases
accessLevelPublic
2022 115 170
Impact of Latent Tuberculosis on DiabetesThe journal of infectious diseases
accessLevelRestricted
2022 216 0
Accelerating investigation of new HIV drugs in pregnancy : advancing the research agenda from theory to actionJournal of the International AIDS Society
accessLevelPublic
2022 72 32
Use of Ritonavir-Boosted Nirmatrelvir in PregnancyClinical infectious diseases
accessLevelPublic
2022 99 16
Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension periodAIDS
accessLevelPublic
2022 763 163
Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe HypoxemiaJAMA
accessLevelRestricted
2022 168 0
How mHealth Can Contribute to Improving the Continuum of Care: A Scoping Review Approach to the Case of Human Immunodeficiency Virus in Sub-Saharan AfricaPublic health reviews
accessLevelPublic
2022 97 26
Transfer of antiretroviral drugs into breastmilk : a prospective study from the Swiss Mother and Child HIV Cohort StudyJournal of antimicrobial chemotherapy
accessLevelPublic
2022 91 44
A Systematic Molecular Epidemiology Screen Reveals Numerous Human Immunodeficiency Virus (HIV) Type 1 Superinfections in the Swiss HIV Cohort StudyThe journal of infectious diseases
accessLevelRestricted
2022 121 0
Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trialsAIDS
accessLevelRestricted
2022 55 0
How the COVID-19 Pandemic Alters the Landscapes of the HIV and Tuberculosis Epidemics in South Africa: A Case Study and Future DirectionsEpidemiologia
accessLevelPublic
2022 78 107
VIH et Covid-19 : deux pandémies virales en interactionRevue médicale suisse
accessLevelPublic
2022 71 57
Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trialClinical and translational science
accessLevelPublic
2022 147 90
Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort studyThe journal of antimicrobial chemotherapy
accessLevelRestricted
2022 99 0
Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trialResearch and practice in thrombosis and haemostasis
accessLevelPublic
2022 241 237
Anticholinergic and sedative medications are associated with neurocognitive performance of well treated people with human immunodeficiency virusOpen forum infectious diseases
accessLevelPublic
2022 89 75
Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative studyHIV medicine
accessLevelPublic
2022 357 125
Quantifying and predicting ongoing Human Immunodeficiency Virus Type 1 (HIV-1) transmission dynamics in Switzerland using a distance-based clustering approachThe journal of infectious diseases
accessLevelRestricted
2022 133 2
A highly virulent variant of HIV-1 circulating in the NetherlandsScience
accessLevelPublic
2022 189 45
Bas les masques, et après ?Revue médicale suisse
accessLevelPublic
2022 58 46
Risk Factors and Incidence of Sexually Transmitted Infections in the Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2022 209 180
Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort StudyThe Journal of infectious diseases
accessLevelPublic
2022 136 135
Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patientsBMC infectious diseases
accessLevelPublic
2022 136 64
Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS)HIV medicine
accessLevelPublic
2022 111 42
Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)International journal of epidemiology
accessLevelRestricted
2022 254 0
Approaches to accelerating the study of new antiretrovirals in pregnancyJournal of the International AIDS Society
accessLevelPublic
2022 71 82
Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trialBritish journal of clinical pharmacology
accessLevelRestricted
2021 212 0
Cyber harassment of female scientists will not be the new normThe Lancet Infectious Diseases
accessLevelPublic
2021 253 194
Network Analysis of Outpatients to Identify Predictive Symptoms and Combinations of Symptoms Associated With Positive/Negative SARS-CoV-2 Nasopharyngeal SwabsFrontiers in Medicine
accessLevelPublic
2021 214 123
Predicting, Diagnosing, and Treating Acute and Early HIV Infection in a Public Sector Facility in EswatiniJournal of acquired immune deficiency syndromes
accessLevelPublic
2021 178 106
Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIVClinical infectious diseases
accessLevelRestricted
2021 183 0
Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort StudyOpen Forum Infectious Diseases
accessLevelPublic
2021 313 151
Effect of Rosuvastatin Therapy on Biomarkers of Inflammation and Immune Activation in People With Human Immunodeficiency Virus at Intermediate Cardiovascular RiskThe journal of infectious diseases
accessLevelRestricted
2021 242 9
Kaposi sarcoma in antiretroviral therapy-treated people with HIV: a wake-up call for research on human herpesvirus-8AIDS
accessLevelPublic
2021 256 207
Predictors of virological failure and time to viral suppression of first-line integrase inhibitor-based antiretroviral treatmentClinical infectious diseases
accessLevelPublic
2021 198 107
The role of Human Immunodeficiency Virus (HIV) asymptomatic status when starting antiretroviral therapy on adherence and treatment outcomes and implications for test and treat: the swiss HIV Cohort StudyClinical Infectious Diseases
accessLevelRestricted
2021 154 0
VIH/sida - VIH au temps du Covid-19 : rencontre de deux pandémiesRevue médicale suisse
accessLevelPublic
2021 206 94
Nouveautés dans le diagnostic du VIHForum médical suisse
accessLevelPublic
2021 263 264
Caring for people living with HIV during the global coronavirus disease 2019 pandemicAIDS
accessLevelRestricted
2021 236 0
Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort StudyHIV medicine
accessLevelRestricted
2021 323 0
Alcohol consumption and neurocognitive deficits in people with well-treated HIV in SwitzerlandPloS one
accessLevelPublic
2021 210 287
Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIVAIDS
accessLevelPublic
2021 208 96
Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxisNature communications
accessLevelPublic
2021 80 10
Weight gain stopping/switch rules for antiretroviral clinical trialsAIDS
accessLevelPublic
2021 183 64
Prophylaxis for COVID-19: a systematic reviewClinical microbiology and infection
accessLevelPublic
2021 85 80
Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequityThe journal of antimicrobial chemotherapy
accessLevelRestricted
2021 173 0
Identifying and characterizing trans women in the swiss HIV Cohort Study as an epidemiologically distinct risk groupClinical Infectious Diseases
accessLevelRestricted
2021 193 0
Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized TrialEClinicalMedicine
accessLevelPublic
2021 636 142
Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort StudyAnnals of internal medicine
accessLevelRestricted
2021 206 0
Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase InhibitorsClinical infectious diseases
accessLevelRestricted
2021 176 0
Representations and Willingness of People Living With HIV in Switzerland to Participate in HIV Cure Trials: The Case of Gene-Modified Cell TherapiesJournal of acquired immune deficiency syndromes
accessLevelRestricted
2021 172 0
Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort StudyThe journal of infectious diseases
accessLevelPublic
2021 99 23
Impact of rosuvastatin on atherosclerosis in people with hiv at moderate cardiovascular risk: a randomised, controlled trialAIDS
accessLevelPublic
2021 668 182
Clinical outcomes of 2-drug regimens vs 3-drug regimens in antiretroviral treatment-experienced people living with Human Immunodeficiency VirusClinical infectious diseases
accessLevelPublic
2021 165 126
The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort StudyJournal of clinical medicine
accessLevelPublic
2021 78 54
Possible link between anosmia and COVID-19: sniffing out the truthEuropean Archives of Oto-Rhino-Laryngology
accessLevelPublic
2020 192 161
Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study : 1980-2018Antiviral therapy
accessLevelRestricted
2020 67 0
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelinesThe Lancet HIV
accessLevelPublic
2020 222 99
Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristicsAmerican Heart Journal
accessLevelPublic
2020 250 101
Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort StudyClinical Infectious Diseases
accessLevelRestricted
2020 229 0
Clinicopathologic Aspects of a Papulovesicular Eruption in a Patient With COVID-19JAMA Dermatology
accessLevelRestricted
2020 311 0
Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK StudyJournal of the American College of Cardiology
accessLevelPublic
2020 408 136
Buyers' club : une alternative pour l'accès au traitement ?Revue médicale suisse
accessLevelPublic
2020 404 190
Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort StudyThe journal of infectious diseases
accessLevelPublic
2020 208 174
Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIVPLoS biology
accessLevelPublic
2020 92 18
Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costsSwiss Medical Weekly
accessLevelPublic
2020 503 342
Towards the real-time inclusion of sex- and age-disaggregated data in pandemic responsesBMJ global health
accessLevelPublic
2020 91 36
Mycobaterium fortuitum disseminated infection in an immunocompetent patient without predisposing factorsBMJ case reports
accessLevelRestricted
2020 180 0
Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trialPLoS medicine
accessLevelPublic
2020 217 161
Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection: A case reportMedicine (Baltimore)
accessLevelPublic
2020 383 115
HIV and antiretroviral therapy-related fat alterationsNature Reviews. Disease Primers
accessLevelRestricted
2020 217 20
The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profileHIV Medicine
accessLevelPublic
2020 404 180
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysisEClinicalMedicine
accessLevelPublic
2020 98 43
First reported case of Rothia dentocariosa spondylodiscitis in an immunocompetent patientIDCases
accessLevelPublic
2020 520 213
How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?HIV medicine
accessLevelPublic
2020 114 28
Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral TherapyOpen Forum Infectious Diseases
accessLevelPublic
2020 231 113
Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT AngiographyOpen forum infectious diseases
accessLevelPublic
2020 135 83
Heritability of the HIV-1 reservoir size and decay under long-term suppressive ARTNature Communications
accessLevelPublic
2020 256 60
Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patientsClinical Infectious Diseases
accessLevelRestricted
2020 362 3
C-terminus apoa-1 mimetic peptides to detect cognate auto-antibodies and reverse HIV-induced foam cell formationAtherosclerosis
accessLevelRestricted
2020 243 0
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19 : initial assessmentJournal of the International AIDS Society
accessLevelPublic
2020 69 12
Dexamethasone and remdesivir: finding method in the COVID-19 madnessThe Lancet microbe
accessLevelPublic
2020 243 33
Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort SettingJournal of Acquired Immune Deficiency Syndromes
accessLevelPublic
2020 229 94
Cobicistat : A case of mislabelled drug-drug interaction risk?British journal of clinical pharmacology
accessLevelPublic
2020 67 13
Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trialBMJ Open
accessLevelPublic
2020 263 102
VIH: prévention, traitement et perspectivesRevue médicale suisse
accessLevelPublic
2020 376 213
Impact of the M184V/I Mutation on the efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV treatment-experienced patientsOpen Forum Infectious Diseases
accessLevelPublic
2019 298 234
Next-Generation Sequencing for the Diagnosis of Challenging Culture-Negative EndocarditisFrontiers in Medicine
accessLevelPublic
2019 381 227
Female Genital Schistosomiasis and HIV: Research Urgently Needed to Improve Understanding of the Health Impacts of This Important CoinfectionJournal of acquired immune deficiency syndromes
accessLevelRestricted
2019 185 0
Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African CountriesJMIR mhealth and uhealth
accessLevelPublic
2019 196 60
Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohortAtherosclerosis
accessLevelRestricted
2019 429 1
Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against OsteoporosisOsteoporosis International
accessLevelRestricted
2019 355 1
Nouveautés dans le dépistage, la prévention et la prise en charge du VIH en 2018Revue médicale suisse
accessLevelPublic
2019 68 15
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trialsLancet
accessLevelRestricted
2019 91 0
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling studyThe lancet. HIV.
accessLevelPublic
2019 79 51
Reply to “Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis” by S. Noe, H. Jaeger, E. WolfOsteoporosis international
accessLevelRestricted
2019 48 0
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherenceThe journal of antimicrobial chemotherapy
accessLevelRestricted
2019 81 0
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1New England Journal of Medicine
accessLevelPublic
2019 286 99
Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017Journal of the International AIDS society
accessLevelPublic
2019 385 141
A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, noncommunicable diseases, and opportunistic diseasesThe Journal of Infectious Diseases
accessLevelRestricted
2019 348 0
Why do sub‐Saharan Africans present late for HIV care in Switzerland ?HIV medicine
accessLevelRestricted
2019 84 0
Viral diversity based on next-generation sequencing of HIV-1 provides precise estimates of infection recency and time since infectionThe Journal of Infectious Diseases
accessLevelRestricted
2019 293 0
Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohortBMC infectious diseases
accessLevelPublic
2019 221 57
Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factorsF1000Research
accessLevelPublic
2019 251 93
Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active MetabolitesClinical Pharmacokinetics
accessLevelPublic
2018 726 736
Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysisF1000Research
accessLevelPublic
2018 153 120
Aging and the evolution of comorbidities among HIV-positive individuals in a European cohortAIDS
accessLevelRestricted
2018 181 0
Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort StudyLiver International
accessLevelRestricted
2018 481 0
Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patientsJournal of Infection
accessLevelRestricted
2018 573 1
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimensHIV Medicine
accessLevelPublic
2018 370 161
Expert consensus statement on the science of HIV in the context of criminal lawJournal of the International AIDS Society
accessLevelPublic
2018 126 252
Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort StudyVirus Evolution
accessLevelPublic
2018 380 86
High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 InfectionClinical Infectious Diseases
accessLevelRestricted
2018 400 0
A buyers' club to improve access to hepatitis C treatment for vulnerable populationsSwiss Medical Weekly
accessLevelPublic
2018 1,225 432
Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination ScheduleClinical infectious diseases
accessLevelRestricted
2018 86 0
Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID StudyKidney International Reports
accessLevelPublic
2018 485 153
Traitements antirétroviraux : vers un allègement ?Revue médicale suisse
accessLevelPublic
2018 63 55
The cumulative impact of harm reduction on the swiss HIV epidemic: cohort study, mathematical model, and phylogenetic analysisOpen Forum Infectious Diseases
accessLevelPublic
2018 372 152
Universal test and treat is not associated with sub‐optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trialJournal of the International AIDS Society
accessLevelPublic
2018 128 36
Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite PathogenicityMolecular Biology and Evolution
accessLevelPublic
2018 499 200
Will NNRTIs be driving forward again ?The lancet. HIV
accessLevelRestricted
2018 52 0
Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patientAnnals of Hematology
accessLevelRestricted
2018 396 0
Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO studyHIV Medicine
accessLevelPublic
2018 327 100
Time to overcome pretreatment HIV drug resistanceThe Lancet Infectious Diseases
accessLevelPublic
2018 391 213
Managing Advanced HIV Disease in a Public Health ApproachClinical infectious diseases
accessLevelPublic
2018 78 48
Evaluation of the Xpert MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis in MadagascarInternational journal of infectious diseases
accessLevelPublic
2018 205 105
Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?HIV Medicine
accessLevelRestricted
2018 368 0
Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in SwitzerlandHIV Medicine
accessLevelRestricted
2018 600 0
Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative personsEuropean heart journal
accessLevelRestricted
2018 98 0
The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral TherapyClinical infectious diseases
accessLevelPublic
2018 53 11
Anti-inflammatory therapy in well controlled HIV infectionThe Lancet HIV
accessLevelRestricted
2018 432 0
Benefits and risks of rapid initiation of antiretroviral therapyAIDS
accessLevelPublic
2018 469 287
Tracing HIV-1 strains that imprint broadly neutralizing antibody responsesNature
accessLevelRestricted
2018 177 0
Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activityThe Journal of experimental medicine
accessLevelPublic
2018 305 110
Universal test and treat and the HIV epidemic in rural South Africa : a phase 4, open-label, community cluster randomised trialThe lancet. HIV
accessLevelPublic
2018 74 68
Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretroviralsMedicine (Philadelphia)
accessLevelPublic
2017 406 160
Life expectancy in HIV-positive persons in Switzerland: matched comparison with general populationAIDS
accessLevelPublic
2017 410 204
Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysiseLife
accessLevelPublic
2017 492 178
Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysisThe Lancet HIV
accessLevelRestricted
2017 440 0
Bone health in HIV and hepatitis B or C infectionsTherapeutic advances in musculoskeletal disease
accessLevelPublic
2017 541 285
Hepatitis delta-associated mortality in HIV/HBV-coinfected patientsJournal of Hepatology
accessLevelPublic
2017 425 504
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European studyJournal of Antimicrobial Chemotherapy
accessLevelRestricted
2017 416 0
Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort StudyHIV Medicine
accessLevelRestricted
2017 383 0
High prevalence of physical inactivity among patients from the Swiss HIV Cohort StudyAIDS Care
accessLevelPublic
2017 406 564
Human papillomavirus antibody response following HAART initiation among MSMAIDS
accessLevelRestricted
2017 423 0
Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort StudyClinical Infectious Diseases
accessLevelRestricted
2017 391 0
Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort AnalysisClinical Infectious Diseases
accessLevelPublic
2017 403 196
Adverse events of raltegravir and dolutegravirAIDS
accessLevelPublic
2017 423 168
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP)The Lancet HIV
accessLevelRestricted
2017 400 0
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort studyBMC Infectious Diseases
accessLevelPublic
2017 418 171
Blinded by Zika? A missed HIV diagnosis that resulted in optic neuropathy and blindness: a case reportBMC Research Notes
accessLevelPublic
2017 419 203
Mining for pairs: shared clinic visit dates identify steady HIV-positive partnershipsHIV Medicine
accessLevelRestricted
2017 443 0
Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort StudyOpen Forum Infectious Diseases
accessLevelPublic
2017 392 155
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trialThe Lancet HIV
accessLevelRestricted
2017 412 0
Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSMAIDS
accessLevelPublic
2017 588 355
The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular EventsJournal of acquired immune deficiency syndromes
accessLevelRestricted
2016 82 0
Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy : The Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2016 83 28
Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland comparedInternational journal of infectious diseases
accessLevelPublic
2016 511 146
Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventionsHepatology
accessLevelPublic
2016 695 264
Hepatitis C Virus Awareness Among Men Who Have Sex With Men in Southwest SwitzerlandSexually transmitted diseases
accessLevelRestricted
2016 66 0
Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence CountryJournal of Clinical Microbiology
accessLevelRestricted
2016 520 0
HIV-Positive-to-HIV-Positive Liver TransplantationAmerican journal of transplantation
accessLevelPublic
2016 663 398
Determinants of HIV-1 broadly neutralizing antibody inductionNature Medicine
accessLevelPublic
2016 555 405
Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort StudyThe Journal of Infectious Diseases
accessLevelPublic
2016 417 220
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV InfectionThe journal of infectious diseases
accessLevelRestricted
2016 55 0
The 2014–2015 Ebola outbreak in West Africa: Hands OnAntimicrobial Resistance and Infection Control
accessLevelPublic
2016 535 226
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort AnalysisClinical Infectious Diseases
accessLevelRestricted
2016 676 1
HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort StudyClinical Infectious Diseases
accessLevelPublic
2016 513 165
Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and reviewNew microbes and new infections
accessLevelRestricted
2015 608 1
Increases in Condomless Sex in the Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2015 87 28
Corrigendum to "Dolutegravir-based antiretroviral therapy in a severely overweight child with a multi-drug resistant human immunodeficiency virus infection. A case report and review" [New Microbes New Infect] 6 (2015) 1-4]New microbes and new infections
accessLevelRestricted
2015 502 0
Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort StudyBMC infectious diseases
accessLevelPublic
2015 101 56
Hit me with your best shot: dolutegravir - a space in the next WHO guidelines ?AIDS
accessLevelRestricted
2015 77 0
Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in SwitzerlandAIDS
accessLevelRestricted
2015 87 0
Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents : a systematic reviewClinical infectious diseases
accessLevelRestricted
2015 75 0
Is monotherapy maintenance the way forward ?The lancet. HIV
accessLevelPublic
2015 62 39
Reasons for late presentation to HIV care in SwitzerlandJournal of the International AIDS Society
accessLevelPublic
2015 69 20
Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelPublic
2015 97 23
Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisalBMC public health
accessLevelPublic
2015 86 38
Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective studyEuropean journal of clinical investigation
accessLevelPrivate
2015 602 0
The future role of CD4 cell count for monitoring antiretroviral therapyLancet. Infectious diseases
accessLevelRestricted
2015 502 0
Prise en charge du VIH/sida en 2015Revue médicale suisse
accessLevelPublic
2015 72 34
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected personsBMC gastroenterology
accessLevelPublic
2015 75 19
Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in AfricaAIDS
accessLevelPublic
2015 104 69
Evidence on the protective role of high-density lipoprotein (HDL) in HIV-infected individualsCurrent vascular pharmacology
2015 683 0
Syphilis: Diagnostik und BehandlungSwiss Medical Forum
accessLevelPublic
2015 380 806
Generating Evidence to Improve the Response to Neglected Diseases : How Operational Research in a Médecins Sans Frontières Buruli Ulcer Treatment Programme Informed International Management GuidancePLoS neglected tropical diseases
accessLevelPublic
2015 65 10
World Health Organization Guidelines on Postexposure Prophylaxis for HIV : Recommendations for a Public Health ApproachClinical infectious diseases
accessLevelRestricted
2015 57 0
Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortalityAIDS
accessLevelRestricted
2015 74 0
Hyaluronic Acid Filler in HIV-Associated Facial Lipoatrophy: Evaluation of Tissue Distribution and Morphology with MRIDermatology
accessLevelRestricted
2015 763 1
Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General PopulationOpen forum infectious diseases
accessLevelPublic
2015 600 246
Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disordersAIDS research and therapy
accessLevelPublic
2015 621 312
Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCVInternational journal of epidemiology
accessLevelPublic
2014 765 429
Disentangling human tolerance and resistance against HIVPLoS biology
accessLevelPublic
2014 662 332
Clinical significance of the CCR5delta32 allele in hepatitis CPloS one
accessLevelPublic
2014 579 218
The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patientsAIDS
accessLevelRestricted
2014 563 0
Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literatureJournal of the International AIDS Society
accessLevelPublic
2014 580 447
AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to beJournal of the International AIDS Society
accessLevelPublic
2014 627 274
Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patientsAIDS
accessLevelRestricted
2014 567 0
Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapyTM & IH. Tropical medicine and international health
accessLevelPublic
2014 609 495
Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort StudyClinical infectious diseases
accessLevelRestricted
2014 708 0
Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activityAIDS research and therapy
accessLevelPublic
2014 730 929
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysisAIDS
accessLevelRestricted
2014 488 0
Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in ZambiaClinical infectious diseases
accessLevelPublic
2014 722 274
Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in SwitzerlandAmerican journal of epidemiology
accessLevelPublic
2014 861 51
Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wideThe Journal of infectious diseases
accessLevelRestricted
2014 601 0
Lipohypertrophy and metabolic disorders in HIV patients on antiretroviral therapy: a systematic multidisciplinary clinical approachJournal of the International AIDS Society
accessLevelPublic
2014 618 1,370
Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backboneHIV clinical trials
accessLevelRestricted
2014 77 0
Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort StudyAntimicrobial agents and chemotherapy
accessLevelPublic
2014 905 469
Impact of human immunodeficiency virus on the severity of buruli ulcer disease: results of a retrospective study in cameroonOpen forum infectious diseases
accessLevelPublic
2014 524 319
Microstructural alterations of trabecular and cortical bone in long-term HIV-infected elderly men on successful antiretroviral therapyAIDS
accessLevelPublic
2014 809 600
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatmentAntimicrobial agents and chemotherapy
accessLevelRestricted
2014 142 0
Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysisAIDS
accessLevelRestricted
2014 551 2
Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort StudyOpen forum infectious diseases
accessLevelPublic
2014 978 347
Réplication cérébrale du VIH malgré une thérapie antirétrovirale efficace: impact clinique et prise en chargeRevue médicale suisse
accessLevelPublic
2014 801 434
Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infectionThe American journal of cardiology
accessLevelRestricted
2013 622 0
Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence : the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa : study protocol for a cluster randomised controlled trialTrials
accessLevelPublic
2013 103 17
Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infectionThe Journal of infectious diseases
accessLevelRestricted
2013 649 0
Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysisAIDS
accessLevelRestricted
2013 590 0
HIV-infected women in Europe: gender-specific needs and challengesAntiviral therapy
2013 614 0
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort StudyAmerican journal of epidemiology
accessLevelRestricted
2013 667 0
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysisAIDS
accessLevelRestricted
2013 619 0
Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort StudyHIV medicine
accessLevelRestricted
2013 634 0
Clinical Course and Management of Iatrogenic Cushing's Syndrome after Co-Administration of Injected-Triamcinolone and Ritonavir: a Systematic ReviewJournal of Antivirals and Antiretrovirals
accessLevelPublic
2013 1,226 303
Les os des personnes infectées par le VIH sont-ils si fragiles?Revue médicale suisse
accessLevelRestricted
2013 623 0
The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patientsPLoS computational biology
accessLevelPublic
2013 697 261
HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosisPLOS genetics
accessLevelPublic
2013 927 628
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individualsPharmacogenetics and genomics
accessLevelRestricted
2013 658 0
Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman: case report and review of the literatureAIDS
accessLevelRestricted
2013 632 0
La prophylaxie postexposition dans tous ses étatsRevue médicale suisse
accessLevelRestricted
2013 601 0
VIH/sida : une sélection des nouveautés les plus prometteuses en 2012Revue médicale suisse
accessLevelRestricted
2013 564 2
Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal womenOsteoporosis international
accessLevelPublic
2013 824 292
Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot studyNeurology
accessLevelRestricted
2013 813 1
Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort StudyPloS one
accessLevelPublic
2013 616 563
Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS)Journal of acquired immune deficiency syndromes
accessLevelRestricted
2013 600 0
Pulmonary embolism and iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavirAIDS
accessLevelPublic
2013 569 343
Association of Alcohol Consumption and HIV Surrogate Markers in Participants of the Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelRestricted
2013 568 0
Bénéfices d'un accompagnement psychologique des patients vivant avec le VIHRevue médicale suisse
accessLevelRestricted
2013 726 0
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trialLancet. Infectious diseases
accessLevelRestricted
2013 945 0
Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High FieldPloS one
accessLevelPublic
2013 801 1,156
Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort studyThe Journal of infectious diseases
accessLevelRestricted
2013 644 0
Produits de comblement du visage : dispositifs médicaux ou médicaments ? Implication pour les patients VIH+ atteints de lipoatrophieRevue médicale suisse
accessLevelRestricted
2012 590 0
Efavirenz is not a known teratogenThe Pediatric infectious disease journal
accessLevelRestricted
2012 557 0
Expert reviews: who are they for?Expert opinion on pharmacotherapy
accessLevelRestricted
2012 567 0
Preferred antiretroviral drugs for the next decade of scale upJournal of the International AIDS Society
accessLevelPublic
2012 547 437
Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infectionBritish journal of cancer
accessLevelPublic
2012 581 1,071
Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patientAIDS
accessLevelPublic
2012 630 570
Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settingsHIV/AIDS[1179-1373]
accessLevelPublic
2012 751 894
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavirAIDS
accessLevelRestricted
2012 613 0
Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumoniaAIDS
accessLevelRestricted
2012 667 0
Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosisAntimicrobial agents and chemotherapy
accessLevelPublic
2012 876 1,201
Buruli et VIH: une interaction complexe et peu étudiéeRevue médicale suisse
accessLevelRestricted
2012 515 0
Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infectionJournal of clinical microbiology
accessLevelPublic
2012 972 1,651
Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccinePloS one
accessLevelPublic
2012 767 326
Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensPloS one
accessLevelPublic
2012 638 268
VIH/SIDARevue médicale suisse
accessLevelRestricted
2012 529 1
Outcome of smoking cessation counselling of HIV-positive persons by HIV care physiciansHIV medicine
accessLevelRestricted
2012 594 0
Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemicClinical infectious diseases
accessLevelRestricted
2012 558 0
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaborationInternational journal of epidemiology
accessLevelRestricted
2012 666 0
Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patientsHIV medicine
accessLevelRestricted
2012 719 0
Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort StudyJournal of acquired immune deficiency syndromes
accessLevelRestricted
2012 632 0
Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settingsBMC infectious diseases
accessLevelPublic
2012 623 438
Défis de la co-infection par le virus de l'hépatite C et le VIHRevue médicale suisse
accessLevelRestricted
2012 619 0
Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort StudyHIV medicine
accessLevelRestricted
2012 632 1
Viral load monitoring in resource-limited settings: a medical and public health priorityAIDS
accessLevelRestricted
2012 529 1
Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patientsPloS one
accessLevelPublic
2012 628 226
Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011Clinical infectious diseases
accessLevelPublic
2012 631 556
Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infectionsAIDS
accessLevelPublic
2012 737 434
Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinicJournal of acquired immune deficiency syndromes
accessLevelRestricted
2011 73 0
Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipientsHaematologica
accessLevelPublic
2011 1,043 595
Ageing with HIV : medication use and risk for potential drug-drug interactionsJournal of antimicrobial chemotherapy
accessLevelRestricted
2011 55 0
Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexualsWorld journal of gastroenterology
accessLevelPublic
2011 941 640
Successful efavirenz dose reduction guided by therapeutic drug monitoringAntiviral therapy
accessLevelRestricted
2011 55 0
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysisAIDS
accessLevelRestricted
2011 62 0
Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center studyArthritis and rheumatism
accessLevelRestricted
2011 867 8
Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and SwitzerlandPloS one
accessLevelPublic
2011 1,276 360
Co-infection tuberculose et VIH: enjeux thérapeutiquesRevue médicale suisse
accessLevelRestricted
2011 655 0
Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients : The ACHIEV2E Collaboration Study GroupClinical infectious diseases
accessLevelRestricted
2011 99 0
VIH/SIDA : nombreuses nouveautésRevue médicale suisse
accessLevelPublic
2011 71 107
A randomized crossover study to compare efavirenz and etravirine treatmentAIDS
accessLevelRestricted
2011 101 0
Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settingsHIV/AIDS
accessLevelPublic
2011 743 537
The first decade of antiretroviral therapy in AfricaGlobalization and health
accessLevelPublic
2011 75 16
HIV treatment for preventionJournal of the International AIDS Society
accessLevelPublic
2011 64 22
Clinical relevance of cytomegalovirus viraemiaHIV medicine
accessLevelRestricted
2011 650 0
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteersAntimicrobial agents and chemotherapy
accessLevelRestricted
2010 632 0
Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort StudyAntiviral therapy
2010 564 0
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavirPharmacogenetics and genomics
accessLevelRestricted
2010 699 0
Improving first-line antiretroviral therapy in resource-limited settingsCurrent opinion in HIV and AIDS
accessLevelRestricted
2010 554 0
Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohortsAIDS
accessLevelRestricted
2010 544 0
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infectionThe Journal of infectious diseases
accessLevelPublic
2010 624 306
Reduction of missed appointments at an urban primary care clinic: a randomised controlled studyBMC family practice
accessLevelPublic
2010 674 375
Treatment of HIV infection with drugs for HSV-2 infectionLancet
accessLevelRestricted
2010 521 0
Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort StudyBritish journal of cancer
accessLevelRestricted
2010 793 1
Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countriesJAMA
accessLevelRestricted
2010 581 0
Optimizing HIV drug therapy
accessLevelPublic
2010 660 1,823
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapyHIV medicine
accessLevelRestricted
2010 621 0
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in CameroonBMC public health
accessLevelPublic
2010 646 245
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patientsAIDS
accessLevelRestricted
2010 591 0
Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemiaClinical infectious diseases
accessLevelRestricted
2010 608 0
Hyaluronic acid injections to fill facial lipoatrophy in the context of a lipodystrophy syndrome associated with HIVDermatologica Helvetica
accessLevelPublic
2010 255 54
No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trialHIV medicine
accessLevelRestricted
2010 582 0
Patient needs and point-of-care requirements for HIV load testing in resource-limited settingsThe Journal of infectious diseases
accessLevelRestricted
2010 580 0
Cognitive dysfunction in HIV patients despite long-standing suppression of viremiaAIDS
accessLevelRestricted
2010 912 1
When to start antiretroviral therapy in resource-limited settings: a human rights analysisBMC international health and human rights
accessLevelPublic
2010 624 329
Health perceptions of African HIV-infected patients and their physiciansPatient education and counseling
accessLevelRestricted
2010 646 0
A new era of antiretroviral drug toxicityAntiviral therapy
2009 588 0
Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoringAIDS
accessLevelRestricted
2009 86 0
Education thérapeutique en maladie infectieuse : l'exemple de l'infection à VIHRevue médicale suisse
2009 645 0
HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trialAIDS
accessLevelRestricted
2009 654 0
Safety and efficacy of once-daily nevirapine dosing: a multicohort studyAntiviral therapy
2009 652 0
Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine : a nested case-control studyClinical infectious diseases
accessLevelRestricted
2009 70 0
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional studyThe Journal of infectious diseases
accessLevelRestricted
2009 593 0
Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patientsAntiviral therapy
accessLevelRestricted
2009 54 0
How developing world concerns need to be part of drug development plans: a case study of four emerging antiretroviralsDrug discovery today
accessLevelRestricted
2008 83 0
Dix ans de lipodystrophie (1998-2008) : un syndrome encore méconnuRevue médicale suisse
accessLevelPublic
2008 580 155
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in CameroonJournal of acquired immune deficiency syndromes
accessLevelRestricted
2008 72 0
The marriage of science and optimized HIV care in resource-limited settingsAIDS
accessLevelRestricted
2008 69 0
Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switchingAIDS
accessLevelRestricted
2008 76 0
Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapyHIV medicine
accessLevelRestricted
2008 77 0
Initial treatment for HIV infection--an embarrassment of richesThe New England journal of medicine
accessLevelRestricted
2008 600 0
Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006HIV medicine
accessLevelRestricted
2008 605 0
10 Jahren Lipodystrophie (1998-2008): Die "Groupe Lipo" der Hôpitaux universitaires de Genève: Ein Beratungsangebot für VIH-Positive mit dem Lipodystrophie-SyndromeDermatologica Helvetica
accessLevelPublic
2008 231 28
Clinical update: adverse effects of antiretroviral therapyLancet
accessLevelRestricted
2007 624 0
HIV viral load monitoring in resource-limited regions: optional or necessary?Clinical infectious diseases
accessLevelRestricted
2007 621 1
Treating HIV in the developing world: getting ahead of the drug development curveDrug discovery today
accessLevelRestricted
2007 61 0
Generic fixed-dose combination antiretroviral treatment in resource-poor settings : multicentric observational cohortAIDS
accessLevelRestricted
2006 76 0
Field assessment of generic antiretroviral drugs : a prospective cohort study in CameroonAntiviral therapy
accessLevelRestricted
2005 86 0
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudineAIDS
accessLevelRestricted
2004 67 0
Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapyClinical infectious diseases
accessLevelRestricted
2004 65 0
First-line and second-line antiretroviral therapyLancet
accessLevelRestricted
2004 63 0
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trialLancet
accessLevelRestricted
2004 81 0
HIV drug resistanceNew England journal of medicine
accessLevelPublic
2004 48 45
Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapyAIDS
accessLevelRestricted
2003 540 0
Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans FrontièresAIDS
accessLevelRestricted
2003 51 0
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack